Frontlight ResearchEarly access
CompletedNo phase
Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients
Key facts
- Who runs it
- Uriach Consumer Healthcare
- Where
- Spain4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 533 people enrolled
- Started
- 22 Sept 2022
- Ended
- 22 Nov 2023
- Type of study
- Observational, 2 groups
- Treatments tested
- carboxymethyl β-glucan
- Record updated
- 10 January 2024
Who can take part
- Age
- 25 years to 65 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 28 criteriaShow less
Other criteria
- TREATMENT GROUP
- INCLUSION:
- Women aged between 25 and 65 years (inclusive)
- Histological cervical cytology results reported as ASCUS, LSIL/CIN1, with a positive cervical PCR determination for high-risk HPV (genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
- Patients currently undergoing treatment with the combination of carboxymethyl B-glucan and polycarboxyl (for at least 15 days prior to study initiation)
- Capable of reading and comprehending the patient information sheet and the informed consent form
- Willing to participate in the study and sign the informed consent form; EXCLUSION:
- Cervical cytology indicating suspected invasive cervical cancer
- Ongoing or recent pregnancy terminated within six weeks of the study commencement
- Clinically significant immunodeficiency-linked pathology
- Active or terminated immunosuppressive treatment within six months of study entry. Specifically, in the case of corticosteroids, women will be excluded if they are currently or recently receiving corticosteroid treatment (defined as within two weeks prior to study entry) or if they have undergone two or more cycles of corticosteroids at doses equal to or greater than 20 mg/day of Prednisone (or equivalent) orally or parenterally for at least one week's duration in the year prior to study entry
- Undiagnosed abnormal genital bleeding
- Total hysterectomy
- Documented history of cervical pathology caused by HPV
- Contraindications to the use of the combination of Carboxymethyl B-glucan and polycarboxyl, or known allergies to any of its components; CONTROL GROUP; INCLUSION:
- Women aged between 25 and 65 years (inclusive)
- Histological cervical cytology results reported as ASCUS, LSIL/CIN1, with a positive cervical PCR determination for high-risk HPV (genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
- Patients not currently undergoing treatment for HPV
- Capable of reading and comprehending the patient information sheet and the informed consent form
- Willing to participate in the study and sign the informed consent form; EXCLUSION:
- Cervical cytology indicating suspected invasive cervical cancer
- Ongoing or recent pregnancy terminated within six weeks of the study commencement
- Clinically significant immunodeficiency-linked pathology
- Active or terminated immunosuppressive treatment within six months of study entry. Specifically, in the case of corticosteroids, women will be excluded if they are currently or recently receiving corticosteroid treatment (defined as within two weeks prior to study entry) or if they have undergone two or more cycles of corticosteroids at doses equal to or greater than 20 mg/day of Prednisone (or equivalent) orally or parenterally for at least one week's duration in the year prior to study entry
- Undiagnosed abnormal genital bleeding
- Total hysterectomy
- Documented history of cervical pathology caused by HPV
- Concurrent participation in a clinical study of an investigational drug that could interfere with the current study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Prospective, Controlled, Multicentre, Real Clinical Practice Study. Effectiveness of Carboxymethyl β-Glucan treatment in high-risk HPV+ patients
The 2 groups in the trial
- CONTROL GROUP
For the duration of the study, standard clinical practice will be followed wait and see strategy, without administering carboxymethyl-b-glucan treatment.
- TREATMENT GROUP
For a period of three months, patients will be administered once daily treatment with Carboxymethyl β-glucan and Polycarbophil
Treatment: carboxymethyl β-glucan
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Efficacy and Safety of the Local Treatment of Carboxymethyl Beta-glucan and Polycarbophil in Patients With Normal Cytology/ASCUS/LSIL (CIN1) With HPV+ PCR Determination
- Record updated
- 10 January 2024